Clinical Trial Update: Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) [Phase 3]

View source ↗

Summary

Phase 3 immunobridging study of the 9-valent HPV vaccine (V503/Gardasil-9) in Chinese females aged 9–45, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2026-04-06